Abstract
Empagliflozin belongs to the new class of drugs for the treatment of heart failure, sodium-glucose co-transporter type 2 inhibitors. Results of the EMPEROR-Reduced, EMPEROR-Preserved and EMPULSE trials confirmed the clinical benefits of empagliflozin over the whole spectrum of symptomatic heart failure. The present article provides clinicians with practical guidance regarding empagliflozin therapy in HF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have